Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Former US Device Center Official Is Now Gottlieb's Chief Of Staff

Executive Summary

US FDA Commissioner Scott Gottlieb has appointed Lauren Silvis as his chief of staff. Silvis has been acting in the role for a few months, following a two-year stint in a top policy post at CDRH.

You may also be interested in...

Attorney Ellen Flannery Takes Top FDA Device-Policy Slot

The long-time Covington & Burling attorney joined US FDA last month as the deputy center director for policy at the device center.

US FDA Gets A New Lawyer: Rebecca Wood Named Chief Counsel

Former Sidley Austin partner brings a wealth of experience in drug product liability litigation and federal preemption. She replaces agency veteran Elizabeth Dickinson, who will stay on as senior deputy to the chief counsel.

FDA Device Center Names New Deputy Policy Director

Almost a year after Nancy Stade stepped down as deputy policy director, Lauren Silvis has been named to take on the role, which is critical to developing CDRH policy, especially as the agency is pursuing a paradigm shift in premarket data requirements.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts